- Home
- PAAC vs NRXP Comparison
PAAC vs NRXP Comparison
Compare PAAC & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
N/A
Current Price
$7.33
Company Overview
Basic Information| Metric | PAAC | NRXP |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.5M | 153.2M |
| IPO Year | 2025 | 2017 |
Fundamental Metrics
Financial Performance| Metric | PAAC | NRXP |
|---|---|---|
| Price | $9.98 | $7.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $38.25 |
| AVG Volume (30 Days) | 11.9K | ★ 1.2M |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,225,000.00 |
| Revenue This Year | N/A | $2,547.84 |
| Revenue Next Year | N/A | $1,591.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.93 | $1.65 |
| 52 Week High | $10.15 | $5.06 |
Technical Indicators
Market Signals| Indicator | PAAC | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 52.11 | 48.63 |
| Support Level | $9.93 | $3.45 |
| Resistance Level | $10.04 | $3.67 |
| Average True Range (ATR) | 0.01 | 0.29 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 40.00 | 39.30 |
Price Performance
Historical Comparison PAAC
NRXP
About PAAC Proem Acquisition Corp I Ordinary Shares
Proem Acquisition Corp I is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.